Carbonic anhydrase IX (CA9) catalyses the interconversion of carbon dioxide to carbonic acid and bicarbonate and is considered a putative biomarker of tumour hypoxia. We set out to evaluate the prognostic significance of CA9 in prostate cancer.
Plasma samples were assessed from 68 men with high-risk localised prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT), and 20 men with castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy between 2010 and 2012 at the Princess Margaret Cancer Centre, Canada.
Of the 68 patients with high-risk localised prostate cancer, 57 underwent RP and 11 underwent RT. Baseline CA9 was not associated with recurrence or prostate-specific antigen in either group (p=0.98 and 0.20, respectively). CA9 levels before chemotherapy correlated with overall survival (r=-0.37; two-sided p=0.11).
Baseline CA9 in men with CRPC may portend a more aggressive prostate cancer phenotype with poorer survival.
Anticancer research. 2016 Sep [Epub]
Alan D Smith, Mathew Truong, Rob Bristow, Paul Yip, Michael F Milosevic, Anthony M Joshua
Princess Margaret Cancer Centre, Toronto, ON, Canada ., Department of Biochemistry, University of Toronto, Toronto, ON, Canada., Princess Margaret Cancer Centre, Toronto, ON, Canada.